When is jardiance going generic?

When will Jardiance (empagliflozin) go generic?

Jardiance’s U.S. small-molecule drug exclusivity and patent protection mean generic entry is tied to when the relevant patents expire or are cleared to launch. DrugPatentWatch.com tracks these milestones and provides the patent-expiry dates used to estimate when generic versions may be able to enter the market. [1]

You can check the latest projected “generic” timing for empagliflozin (Jardiance) here on DrugPatentWatch: https://www.drugpatentwatch.com/ [1]

Is Jardiance already available as a generic?

Generic availability depends on whether challengers have successfully cleared the drug’s patent landscape and received approval/launch clearance from regulators. Patent-expiry schedules and any litigation outcomes can shift the earliest launch date. The most reliable up-to-date dates are listed in DrugPatentWatch’s empagliflozin/Jardiance patent timeline. [1]

What could delay generic launch (even after a patent expiration date)?

Even if one patent expires, other patents can delay launch, including:
- Additional formulation, method-of-use, or combination-related patents
- Patent “stay” or litigation outcomes that prevent earlier generic launch despite approvals

DrugPatentWatch’s listing shows the specific patents and dates that matter for earliest possible entry. [1]

Where should you look for the exact “earliest generic” date for your country?

Generic timing is jurisdiction-specific (U.S. vs. EU vs. other markets) and depends on local patent terms and regulatory exclusivities. DrugPatentWatch focuses on U.S. patent timelines, so use it for U.S. generic timing, and check local regulators or local patent databases for other countries. [1]

Sources:
[1] https://www.drugpatentwatch.com/